Literature DB >> 28209683

Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.

Solomon Mamakwa1, Meldon Kahan2, Dinah Kanate3, Mike Kirlew4, David Folk5, Sharon Cirone6, Sara Rea7, Pierre Parsons8, Craig Edwards9, Janet Gordon10, Fiona Main11, Len Kelly12.   

Abstract

OBJECTIVE: To evaluate established opioid addiction treatment programs that use traditional healing in combination with buprenorphine-naloxone maintenance treatment in 6 First Nations communities in the Sioux Lookout region of northwestern Ontario.
DESIGN: Retrospective cohort study.
SETTING: Six First Nations communities in northwestern Ontario. PARTICIPANTS: A total of 526 First Nations participants in opioid-dependence treatment programs. INTERVENTION: Buprenorphine-naloxone substitution therapy and First Nations healing programming. MAIN OUTCOME MEASURES: Retention rates and urine drug screening (UDS) results.
RESULTS: Treatment retention rates at 6, 12, and 18 months were 84%, 78%, and 72%, respectively. We estimate that the rate at 24 months will also be more than 70%. The UDS programming varied and was implemented in only 1 community. Initially urine testing was voluntary and it then became mandatory. Screening with either method found the proportion of urine samples with negative results for illicit opioids ranged between 84% and 95%.
CONCLUSION: The program's treatment retention rates and negative UDS results were higher than those reported for most methadone and buprenorphine-naloxone programs, despite a patient population where severe posttraumatic stress disorder is endemic, and despite the programs' lack of resources and addiction expertise. Community-based programs like these overcome the initial challenge of cultural competence. First Nations communities in other provinces should establish their own buprenorphinenaloxone programs, using local primary care physicians as prescribers. Sustainable core funding is needed for programming, long-term aftercare, and trauma recovery for such initiatives. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28209683      PMCID: PMC5395389     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

1.  Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence.

Authors:  Carol J Strike; William Gnam; Karen Urbanoski; Benedikt Fischer; David C Marsh; Margaret Millson
Journal:  Addict Behav       Date:  2005-06       Impact factor: 3.913

2.  Evaluation of an inpatient medical withdrawal program in rural Ontario: a 1-year prospective study.

Authors:  Niki Kiepek; Bobbi Groom; Debbie Toppozini; Kara Kakekagumick; Jill Muileboom; Len Kelly
Journal:  Can J Rural Med       Date:  2015

3.  Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.

Authors:  Dinah Kanate; David Folk; Sharon Cirone; Janet Gordon; Mike Kirlew; Terri Veale; Natalie Bocking; Sara Rea; Len Kelly
Journal:  Can Fam Physician       Date:  2015-02       Impact factor: 3.275

4.  Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.

Authors:  S M Apelt; N Scherbaum; J Gölz; M Backmund; M Soyka
Journal:  Pharmacopsychiatry       Date:  2013-01-04       Impact factor: 5.788

5.  Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications.

Authors:  Len Kelly; Joe Dooley; Helen Cromarty; Bryanne Minty; Alanna Morgan; Sharen Madden; Wilma Hopman
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

Review 6.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

7.  First Nations women's mental health: results from an Ontario survey.

Authors:  Harriet L MacMillan; Ellen Jamieson; Christine A Walsh; Maria Y-Y Wong; Emily J Faries; Harvey McCue; Angus B MacMillan; David Dan R Offord
Journal:  Arch Womens Ment Health       Date:  2008-05-21       Impact factor: 3.633

8.  Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Authors:  Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling
Journal:  J Stud Alcohol Drugs       Date:  2013-07       Impact factor: 2.582

9.  Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.

Authors:  Paul J Whelan; Kimberly Remski
Journal:  J Neurosci Rural Pract       Date:  2012-01

10.  Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.

Authors:  Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

View more
  18 in total

1.  Indigenous-led health care partnerships in Canada.

Authors:  Lindsay Allen; Andrew Hatala; Sabina Ijaz; Elder David Courchene; Elder Burma Bushie
Journal:  CMAJ       Date:  2020-03-02       Impact factor: 8.262

2.  First Nations hepatitis C virus infections: Six-year retrospective study of on-reserve rates of newly reported infections in northwestern Ontario.

Authors:  Janet Gordon; Natalie Bocking; Kathy Pouteau; Terri Farrell; Gareth Ryan; Len Kelly
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

Review 3.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

4.  Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives.

Authors:  Kamilla L Venner; Dennis M Donovan; Aimee N C Campbell; Dennis C Wendt; Traci Rieckmann; Sandra M Radin; Sandra L Momper; Carmen L Rosa
Journal:  Addict Behav       Date:  2018-05-23       Impact factor: 3.913

Review 5.  The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?

Authors:  Stine Bordier Høj; Nanor Minoyan; Andreea Adelina Artenie; Jason Grebely; Julie Bruneau
Journal:  Can Liver J       Date:  2018-07-17

Review 6. 

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

7.  Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota.

Authors:  Thaius Boyd; Jordan Stipek; Alex Kraft; Judge Muskrat; Kevin A Hallgren; Clinton Alexander; Brenna Greenfield
Journal:  Drug Alcohol Depend       Date:  2021-03-18       Impact factor: 4.492

8.  A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.

Authors:  Kristen A Morin; Joseph K Eibl; Graham Gauthier; Brian Rush; Christopher Mushquash; Nancy E Lightfoot; David C Marsh
Journal:  Harm Reduct J       Date:  2020-07-23

Review 9.  Global incidence of suicide among Indigenous peoples: a systematic review.

Authors:  Nathaniel J Pollock; Kiyuri Naicker; Alex Loro; Shree Mulay; Ian Colman
Journal:  BMC Med       Date:  2018-08-20       Impact factor: 8.775

Review 10.  Seven Core Principles of Substance Use Treatment System Design to Aid in Identifying Strengths, Gaps, and Required Enhancements.

Authors:  Brian Rush; Karen Urbanoski
Journal:  J Stud Alcohol Drugs Suppl       Date:  2019-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.